EFTR.png
eFFECTOR Therapeutics Announces Reverse Stock Split
09 janv. 2024 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
08 déc. 2023 08h15 HE | eFFECTOR Therapeutics, Inc.
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
28 nov. 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
15 nov. 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 16h14 HE | eFFECTOR Therapeutics, Inc.
Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
06 nov. 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
24 oct. 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
11 sept. 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
30 août 2023 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08 août 2023 16h01 HE | eFFECTOR Therapeutics, Inc.
Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC)...